Drug intelligence / Profile preview

GW784568X

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Intranasal

Overview

GW784568X is a small molecule drug developed by GSK (GlaxoSmithKline) as a glucocorticoid receptor agonist. It was investigated for the treatment of allergic rhinitis, specifically to assess its effects on allergic rhinitis symptoms in clinical trials. The drug acts as an agonist at the glucocorticoid receptor, modulating inflammatory responses associated with allergic conditions. Development of GW784568X has been discontinued and it is not marketed for any indication[1][2][3].

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on GW784568X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW784568X.

Explore the full profile